Advances in research of bispecific antibodies for antivirus therapy.

Guanxing Zhai; Lu LU; Huili LU; Daijie Chen

Return

Advances in research of bispecific antibodies for antivirus therapy.

Author: Guanxing ZHAI ¹ ; Lu LU ² ; Huili LU ³ ; Daijie CHEN ³
Author Information

1. College of Life Sciences, Shanghai Normal University, Shanghai 200234, China.
2. School of Biological Engineering, East China University of Science and Technology, Shanghai 200237, China.
3. School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Publication Type:Journal Article
Keywords: antibody engineering; antibody therapy; antivirus; bispecific antibody; immunotherapy
MeSH: Antibodies, Bispecific; therapeutic use; Antibodies, Monoclonal; Epitopes; Humans; Immunotherapy; Virus Diseases
From: Chinese Journal of Biotechnology 2019;35(7):1174-1183
CountryChina
Language:Chinese
Abstract: With the rapid development of antibody genetic engineering, bispecific antibody technology has been advanced. They are capable of binding two or more different epitopes simultaneously, thus offering specific advantages over natural monoclonal antibodies in immunotherapy. Bispecific antibodies have been successfully used in cancer therapy (e.g. melanoma, Hodgkin's lymphoma, liver cancer, and stomach cancer) and inflammation therapy (e.g. rheumatoid arthritis, psoriasis and Crohn's disease), but are still in their early stage for viral immunotherapy. In this study, we reviewed the research progress of bispecific antibodies for immunotherapy of virus infections, especially those with good effects in vivo and in vitro, to provide references for the research and development of bispecific antibodies for antivirus treatment.